Article

Cumulative cost pattern comparison of prostate cancer treatments

Department of Medicine, University of California, San Francisco, California 94143, USA.
Cancer (Impact Factor: 4.9). 02/2007; 109(3):518-27. DOI: 10.1002/cncr.22433
Source: PubMed

ABSTRACT Studies that compare prostate cancer treatment costs show wide variation. None compare all contemporary treatment costs, and most focus on initial treatment costs. The authors compared healthcare utilization and cost patterns of prostate cancer treatments over a span of 5.5 years in 4553 newly diagnosed patients stratified by age and risk group.
Contemporary treatment and evaluation patterns for prostate cancer were identified by using CaPSURE, a national disease registry of men with prostate cancer that included ongoing clinical data collection from 31 academic and community urology practices and biennial patient-reported outcome questionnaires that included demography, medical condition, comorbidity, risk measures, and healthcare utilization. Costs of outpatient visits, medications, and hospitalizations were applied from various national sources. Recurrent events analysis (MCF) accounted for left and right censorship. A mixed effects regression model with bootstrapping for skewed cost data quantified the relation between MCF cost, age, and risk.
Prostate-related costs in the first 6 months after treatment were 11,495 dollars, (from 2586 dollars for watchful waiting (WW) to 24,204 dollars for external beam radiation. After 6 months, average cost was only 3044 dollars. Annual cost is 7740 dollars, highest for androgen deprivation therapy (12,590 dollars) and lowest for watch waiting (5843 dollars). Risk and age were significantly related to initial treatment choice. Cumulative cost (42,570 dollars) allowed a better estimate of treatment pattern costs.
The cost burden of prostate cancer is high, but it varies by treatment type even when controlling for disease, age, and stage. Cumulative cost analysis allowed inclusion of adverse events and disease recurrence costs, making new cost comparisons evident among treatments.

Download full-text

Full-text

Available from: David M Latini, Mar 10, 2014
0 Followers
 · 
112 Views
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Executive Summary The Prostate Cancer Screening Program at the Markey Cancer Center co-sponsors prostate cancer screenings with the Prostate Cancer Education Council. All participation, including African-American attendance, has decreased 38% from years 2006 to 2008 and program managers are seeking insight to improve program participation by acquiring knowledge of behavioral and medical characteristics that may influence screening attendance. Because of the higher incidence of prostate cancer in African-American men (ACS, 2008), a specific program goal is also to increase screening attendance for this minority population. Problem Statement Questions that assess participant behavior, personal, and family medical history are analyzed to determine specific relevant variables that may influence participation. A general description of the data and participation rates, for new and returning participants, is presented. Variable analysis will be conducted for certain behavioral factors and grouped variable analyses will be conducted for urinary, sexual and testosterone health symptoms. Relevant variables with predict returning participant behaviors.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. A parallel manipulator concept using bistable polymer actuators has been developed to perform prostate cancer biopsy and deliver therapy within the bore of a Magnetic Resonance Imaging (MRI) scanner. The dielectric elastomer actuators (DEA) used in this manipulator concept are promising for MRI-compatible robotics because they do not interfere with the high magnetic fields of MRI while having good mechanical performance and being low cost. In the past, these actuators have been plagued by robustness problems when used in a continuous manner. Recent studies show that reliability significantly improves when DEAs are used in a bistable manner such as proposed here. Method of Approach. This paper investigates the potential of the proposed manipulator concept by evaluating the positioning accuracy and MRI-compatibility of a laboratory prototype developed for clinically relevant design criteria. Results. An analytical model of the manipulator kinematics is presented. Analytical and experimental results validate that the proposed technology can provide accurate needle placement required to perform prostate cancer treatments. The prototype's MRI compatibility is validated in a 3 Tesla clinical MRI scanner. Conclusions. The parallel manipulator concept using bistable polymer actuators is shown to be a viable approach to perform MRI-guided needle insertions for prostate cancer biopsy and therapy.